The decline in ovarian cancer mortality rates after 2003 can be attributed to advances in treatment, precision medicine, improved preventive strategies, and a reduced disease incidence, according to ...

In an extension trial, apremilast showed sustained clinical benefit and a consistent safety profile in children and ...